Skip to main content

Table 2 Change in best corrected visual acuity (BCVA) according to different baseline characteristics

From: Optical coherence tomography biomarkers in patients with macular edema secondary to retinal vein occlusion treated with dexamethasone implant

  Change in BCVA from baseline to month 6c, n (%)
≥ 5 ≥ 10 ≥ 15 ≤5 pa
Diagnosis
 CRVO 5 (19.2) 5 (20.8) 5 (25.0) 9 (42.9) 0.0728b
 BRVO 21 (80.8) 19 (79.2) 15 (75.0) 12 (57.1)
Treatment status
 Naïve 18 (69.2) 18 (75.0) 14 (70.0) 9 (42.9) 0.0690b
 Previously treated 8 (30.8) 6 (25.0) 6 (30.0) 12 (57.1)
ME durationd
  ≤ 32 days 10 (38.5) 9 (37.5) 9 (45.0) 13 (61.9) 0.1010b
  > 32 days 16 (61.5) 15 (62.5) 11 (55.0) 8 (38.1)
Type of RVO-ME
 SLRS 0 (0.0) 0 (0.0) 0 (0.0) 2 (9.5) 0.1877
 CME 8 (30.8) 7 (29.4) 8 (40.0) 9 (42.9)
 SRD 18 (69.2) 17 (70.8) 12 (60.0) 10 (47.6)
HRF, n (%)
  < 10 5 (19.2) 4 (16.7) 5 (25.0) 6 (28.6) 0.7126
 10–20 14 (53.8) 13 (54.2) 7 (35.0) 7 (33.3)
  > 20 7 (26.9) 7 (29.2) 8 (40.0) 8 (38.1)
ELM, n (%)
 Non-disrupted 6 (23.1) 6 (25.0) 3 (15.0) 4 (19.0) 0.3960
 Partially disrupted 15 (57.7) 13 (54.2) 10 (50.0) 7 (33.3)
 Disrupted 5 (19.2) 5 (20.8) 7 (35.0) 10 (47.6)
DRIL, n (%)
 No 9 (34.6) 8 (33.3) 5 (25.0) 11 (52.4) 0.3391b
 Yes 17 (65.4) 16 (66.7) 15 (75.0) 10 (47.6)
Cysts, n (%)e
  < 100 μm 0 (0.0) 0 (0.0) 0 (0.0) 2 (10.0) 0.2014
 100–200 μm 7 (26.9) 6 (25.0) 3 (15.0) 3 (15.0)
  > 200 μm 19 (73.1) 18 (75.0) 17 (5.5) 15 (75.0)
  1. Abbreviations: BCVA Best corrected visual acuity, CRVO Central retinal vein occlusion, BRVO Branch retinal vein occlusion, EM Macular edema, RVO-ME Macular edema secondary to retinal vein occlusion, SLRS Sponge-like retinal swelling, CME Cystoid macular edema, SRD Serous retinal detachment, HRF Hyperreflective foci, ELM External limiting membrane, DRIL Disorganization of the retinal inner layers
  2. aChi-squared test
  3. bChi-squared for trend test
  4. cLetters in the Early Treatment Diabetic Retinopathy Study (ETDRS) charts
  5. dMedian split
  6. eFifty-six eyes